Pneumococcal Vaccines – Epidemiology Forecast in Asia-Pacific Markets to 2028
- Pages: 32
- Published: March 2020
- Report Code: GDHCER236-20
Streptococcus pneumoniae (S. pneumoniae) is a bacterial organism that causes a number of diseases, ranging from serious to mild infections. Symptoms depend on the part of the body that is infected, and range from fever, chills, and difficulty breathing to stiff neck and confusion. Transmission of S. pneumoniae primarily occurs through respiratory droplets. The term invasive pneumococcal disease (IPD) refers to more severe infections in which the bacterium is isolated from normally sterile sites. IPD is most common in high-risk groups, such as young children and the elderly, where the immune system is more vulnerable.
GlobalData epidemiologists utilized comprehensive, country-specific pneumococcal vaccination rate data and IPD diagnosed incidence rate data from nationally representative public health surveillance systems and databases to arrive at a meaningful, in-depth epidemiological analysis and forecast. Moreover, GlobalData epidemiologists provide detailed dose- and age-specific pneumococcal vaccination rates that are dependent on the routine immunization requirements of each market.
GlobalData epidemiologists forecast that the pneumococcal vaccinated pediatric population in the 5GM will increase from 20,087,973 children vaccinated in 2018 to 22,139,213 children vaccinated in 2028. In the elderly population in four growth markets (4GM: Australia, Japan, South Korea, and urban China) where vaccination in this age group is recommended, GlobalData epidemiologists forecast an increase from 27,444,336 elderly vaccinated in 2018 to 39,002,217 elderly vaccinated in 2028. In the 5GM in 2018, the average pediatric vaccination rate was approximately 75%, while in the 4GM, the average elderly vaccination rate was approximately 45%. Additionally, GlobalData epidemiologists forecast that the diagnosed incident cases of IPD in the 5GM will decrease from 2,038,634 cases in 2018 to 1,880,503 cases in 2028. In the future, continued efforts should focus on establishing national vaccine initiatives and goals and carrying out a targeted, actionable, and effective country-specific approach to overcome vaccine hesitancy, increase vaccine awareness, and ultimately reduce IPD incidence worldwide.
The Pneumococcal Vaccines Epidemiology Report and Model provide an overview of the risk factors and global trends of pneumococcal vaccines in the five growth markets (5GM: Australia, India, Japan, South Korea, and urban China).
This report also includes a 10-year epidemiological forecast for the vaccinated pneumococcal population segmented by age (pediatric and elderly), and diagnosed incident cases of IPD segmented by age (0–4 years, 5–9 years, 10–19 years, and by 10-year age groups up to 80 years and older). Pneumococcal vaccine dosing and age groups included within the forecast were dependent on the routine immunization requirements in each market and the availability of vaccination data. In addition, the epidemiology model corresponding to this report provides IPD diagnosed incident cases segmented into the top ten most common IPD serotypes by age (pediatric and elderly).
The Pneumococcal Vaccines epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
• The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 5GM.
• The Epidemiology Model is easy to navigate, interactive, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.
Reasons to buy
The Pneumococcal Vaccines Epidemiology series will allow you to:
Develop business strategies by understanding the trends shaping and driving the global pneumococcal vaccines market.
Quantify patient populations in the global pneumococcal vaccines market to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the age groups that present the best opportunities for pneumococcal vaccine therapeutics in each of the markets covered.
Understand magnitude of the pneumococcal vaccines population by dose and age.
Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Pneumococcal Vaccines: Executive Summary
2.1 Related Reports
2.2 Upcoming Reports
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.3.1 Pediatric and Elderly Pneumococcal Vaccination Rates
3.3.2 Diagnosed Incidence of Invasive Pneumococcal Disease (Cases per 100,000 Population)
3.4 Forecast Methodology
3.4.2 Sources Not Used
3.4.3 Forecast Assumptions and Methods
3.4.4 Pneumococcal Vaccination Rates in the Pediatric Population
3.4.5 Pneumococcal Vaccination Rates in the Elderly Population
3.4.6 Diagnosed Incident Cases of Invasive Pneumococcal Disease
3.5 Epidemiological Forecast for Pneumococcal Vaccines and Invasive Pneumococcal Disease (2018–2028)
3.5.1 Pneumococcal Vaccinated Pediatric Population
3.5.2 Pneumococcal Vaccinated Elderly Population
3.5.3 Diagnosed Incident Cases of IPD
3.5.4 Age-Specific Diagnosed Incident Cases of IPD
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of Analysis
3.6.3 Strengths of Analysis
4.2 About the Authors
4.2.3 Global Director of Therapy Analysis and Epidemiology
4.2.4 Global Head and EVP of Healthcare Operations and Strategy
4.3 About GlobalData
4.4 Contact Us
List of Tables
Table 1: Risk Factors and Comorbidities for Invasive Pneumococcal Disease
Table 2: Pediatric Pneumococcal Vaccination Rate Trends (%)
Table 3: Elderly Pneumococcal Vaccination Rate Trends (%)
List of Figures
Figure 1: 5GM, Pneumococcal Vaccinated Pediatric Population, Both Sexes, 2018 and 2028
Figure 2: 4GM, Pneumococcal Vaccinated Elderly Population, Both Sexes, 2018 and 2028
Figure 3: 4GM, Diagnosed Incidence of IPD, Both Sexes, All Ages, 2008–2028
Figure 4: India, Diagnosed Incidence of IPD, Both Sexes, All Ages, 2008–2028
Figure 5: 5GM, Sources Used for the Pneumococcal Vaccinated Pediatric Population
Figure 6: 4GM, Sources Used for the Pneumococcal Vaccinated Elderly Population
Figure 7: 5GM, Sources Used for the Diagnosed Incident Cases of IPD
Figure 8: 5GM, Pneumococcal Vaccinated Pediatric Population, Both Sexes, 2018
Figure 9: 4GM, Pneumococcal Vaccinated Elderly Population, Both Sexes, 2018
Figure 10: 5GM, Diagnosed Incident Cases of IPD, Both Sexes, All Ages, 2018
Figure 11: Australia, Japan, and South Korea Age-Specific Diagnosed Incident Cases of IPD, Men and Women, N, 2018
Figure 12: India, Age-Specific Diagnosed Incident Cases of IPD, Men and Women, N, 2018
Figure 13: Urban China, Age-Specific Diagnosed Incident Cases of IPD, Men and Women, N, 2018